Polymorphism of the erythropoietin gene promotor and the development of myelodysplastic syndromes subsequent to multiple myeloma

Leukemia

Volumn 26, Issue 4, 2012, Pages 844-845

  Landgren, O ^a   Ma, W ^b   Kyle, R A ^c   Rajkumar, S V ^c   Korde, N ^a   Albitar, M ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b QUEST DIAGNOSTICS NICHOLS INSTITUTE   (United States)

^c MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN;

ADULT; AGED; ALLELE; BLOOD; CANCER DIAGNOSIS; CANCER PATIENT; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; FOLLOW UP; GENE AMPLIFICATION; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; LETTER; MALE; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; REAL TIME POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; ERYTHROPOIETIN; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROMES; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC;

EID: 84859628323     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2011.262     Document Type: Letter

References (9)

1. Kyle RA, Pierre RV, Bayrd ED. Multiple myeloma and acute myelomonocytic leukemia. N Engl J Med 1970; 283: 1121-1125.
2. Cuzick J, Erskine S, Edelman D, Galton DA. A comparison of the incidence of the myelodysplastic syndrome and acute myeloid leukaemia following melphalan and cyclophosphamide treatment for myelomatosis. A report to the Medical Research Council's working party on leukaemia in adults. Br J Cancer 1987; 55: 523-529. (Pubitemid 17098861)
3. Bergsagel DE, Bailey AJ, Langley GR, MacDonald RN, White DF, Miller AB. The chemotherapy on plasma-cell myeloma and the incidence of acute leukemia. N Engl J Med 1979; 301: 743-748. (Pubitemid 10250478)
4. Govindarajan R, Jagannath S, Flick JT, Vesole DH, Sawyer J, Barlogie B et al. Preceding standard therapy is the likely cause of MDS after autotransplants for multiple myeloma. Br J Haematol 1996; 95: 349-353. (Pubitemid 26360224)
5. Barlogie B, Tricot G, Haessler J, van Rhee F, Cottler-Fox M, Anaissie E et al. Cytogenetically defined myelodysplasia after melphalan-based autotransplantation for multiple myeloma linked to poor hematopoietic stem-cell mobilization: the Arkansas experience in more than 3,000 patients treated since 1989. Blood 2008; 111: 94-100.
6. Anonymous. Acute leukaemia and other secondary neoplasms in patients treated with conventional chemotherapy for multiple myeloma: a Finnish Leukaemia Group study. Eur J Haematol 2000; 65: 123-127.
7. Hasskarl J, Ihorst G, De Pasquale D, Schrottner P, Zerweck A, Wasch R et al. Association of multiple myeloma with different neoplasms: systematic analysis in consecutive patients with myeloma. Leuk Lymphoma 2011; 52: 247-259.
8. Ma W, Kantarjian H, Zhang K, Zhang X, Wang X, Chen C et al. Significant association between polymorphism of the erythropoietin gene promoter and myelodysplastic syndrome. BMC Med Genet 2010; 11: 163.
9. Landgren O, Polliack A, Tadmor T. Associations between multiple myeloma and other malignancies. Leuk Lymphoma 2011; 52: 161-162.